Sta Znaci RANDOMISATION na Hrvatskom - Hrvatski Prijevod

• randomizacija
• randomizacije
• randomizaciji

Primjeri korištenja Randomisation na Engleski i njihovi prijevodi na Hrvatskom

DRL at screening and Randomisation.
RPP-om pri probiru i randomizaciji.

Randomisation was stratified by HCV genotype 1, 2, 3, 4, 5, 6 and indeterminate.
Randomizacija je stratificirana prema genotipu(1, 2, 3, 4, 5, 6 i neutvrđeno) HCV-a.

Adjusted for corticosteroid use at randomisation.
Prilagođeno za primjenu kortikosteroida na randomizaciji.

Randomisation was stratified by Sokal risk score at the time of diagnosis.
Randomizacija je bila stratificirana po pokazatelju rizika prema Sokalu u vrijeme postavljanja dijagnoze.

A- Logistic regression model adjusted for randomisation stratification variables.
A- Model logističke regresije prilagođen za varijable randomizirane u stratuse.

Basal insulin and sulphonylurea/glinides were discontinued at randomisation.
Pri randomizaciji je prekinuto liječenje bazalnim inzulinom i sulfonilurejom/glinidima.

Randomisation was stratified by tumour PD-L1 status and M stage M0/M1a/M1b versus M1c.
Randomizacija je bila stratificirana prema tumorskom PD-L1 statusu i metastatskom stadiju M0/M1a/M1b naspram M1c.

A total of 111 patients started tolvaptan treatment in an open-label, extension trial, regardless of their previous randomisation.
Ukupno 111 bolesnika počelo je liječenje tolvaptanom u otvorenom produžetku ispitivanja, bez obzira na njihovu prethodnu randomizaciju.

Randomisation was stratified by the presence or absence of cirrhosis and HCV genotype 1a versus 1b.
Randomizacija je bila stratificirana prema prisutnosti ili odsutnosti ciroze i genotipu HCV-a 1a naspram 1b.

Tumour assessments were conducted 12 weeks after randomisation then every 6 weeks for the first year, and every 12 weeks thereafter.
Procjene tumora provedene su 12 tjedana nakon randomizacije, a zatim svakih 6 tjedana tijekom prve godine te svakih 12 tjedana nakon toga.

Randomisation was stratified by screening HIV-1 RNA level< 100,000 copies/ml and> 100,000 copies/ml.
Randomizacija je stratificirana pomoću probira HIV-1 RNK vrijednosti< 100 000 kopija/ml i> 100 000 kopija/ml.

The clinical efficacy and the clinical relevance of Selincro were analysed in patients with a high or very high DRL at screening and randomisation.
Klinička djelotvornost i klinički značaj Selincra analizirani su u bolesnika s visokim ili vrlo visokim RPP-om pri probiru i randomizaciji.

Randomisation was stratified by HCV genotype(1, 2, 4, 6, and indeterminate) and the presence or absence of cirrhosis.
Randomizacija je stratificirana prema genotipu HCV-a(1, 2, 4, 6 i neutvrđen) i prisutnosti ili odsutnosti ciroze.

Week-14 responders(195/282) were analysed for the primary endpoint, which was time from randomisation to loss of response see Table 7.
Bolesnici s odgovorom u 14. tjednu(195/282) bili su uključeni u analizu primarne mjere ishoda, a to je bilo vrijeme od randomizacije do gubitka odgovora vidjeti Tablicu 7.

Randomisation was stratified by screening HIV-1 RNA level≤100,000 copies/ml or> 100,000 copies/ml.
Randomizacija je bila stratificirana prema rezultatima probira na razinu HIV-1 RNK ≤ 100 000 kopija/ml ili> 100 000 kopija/ml.

A significant reduction in the number of HDDs and TAC occurred in some patients in the period between the initial visit(screening) and randomisation due to non-pharmacological effects.
Značajno smanjenje broja DTPP-a i UKA-a javilo se u nekih bolesnika u razdoblju između početnog posjeta(probir) i randomizacije zbog nefarmakoloških učinaka.

Randomisation was stratified by BRAF and tumour PD-L1 status and best response to prior ipilimumab.
Randomizacija je bila stratificirana prema BRAF i tumorskom PD-L1 statusu te najboljem odgovoru na prethodno liječenje ipilimumabom.

In Studies 1(n=579), and 2(n=655), 18%, and 33%, of the total population, respectively, considerably reduced their alcohol consumption in the period between screening and randomisation.
U ispitivanjima 1(n=579) i 2(n=655), 18%, odnosno, 33% od ukupne populacije je značajno smanjilo konzumaciju alkohola u razdoblju između probira i randomizacije.

Randomisation was stratified by prior trastuzumab treatment and number of prior treatments for metastatic disease.
Randomizacija je stratificirana prema prethodnom liječenju trastuzumabom i broju prethodnih liječenja metastatske bolesti.

Proportions of Subjects in the Once Daily versus Twice Daily Abacavir+Lamivudine Randomisation of ARROW with Plasma HIV-1 RNA< 80 copies/ml: Subgroup Analysis by Formulation.
Udio ispitanika s HIV-1 RNK u plazmi< 80 kopija/ml nakon randomizacije za primjenu abakavira+ lamivudina jedanput na dan naspram dvaput na dan u ispitivanju ARROW: analiza podskupina prema formulaciji lijeka.

At randomisation, these patients consumed such a small amount of alcohol that there was little room for further improvement floor effect.
Ovi su bolesnici u trenutku randomizacije konzumirali toliko male količine alkohola da je bilo malo mjesta za daljnja poboljšanja floor effect.

As concerns the patients with high or very high DRL at baseline, 35% of patients experienced improvement due to non-pharmacological effects in the period between the initial visit(screening) and randomisation.
Od bolesnika s visokim ili vrlo visokim RPP-om pri početnim vrijednostima, 35% bolesnika iskusilo je poboljšanje zbog nefarmakoloških učinaka u razdoblju između početnog posjeta(probir) i randomizacije.

The median time from diagnosis to randomisation was 64 months in the dasatinib group and 52 months in the imatinib group.
Medijan vremena od dijagnoze do randomizacije iznosio je 64 mjeseca u skupini koja je primala dasatinib te 52 mjeseca u skupini koja je primala imatinib.

Randomisation was stratified by breast cancer type(operable, locally advanced, or inflammatory) and ER and/or PgR positivity.
Randomizacija je bila stratificirana prema vrsti raka dojke(operabilan, lokalno uznapredovao ili upalni) te prema tome jesu li bolesnice imale pozitivan ER i/ili PgR status.

PFS was defined as the time from randomisation to the earliest date of disease progression or death from any cause, or to the date of censor.
Preživljene bez progresije(PFS) bolesti definirano je kao vrijeme od randomizacije do datuma najranije progresije bolesti ili smrti zbog bilo kojeg uzroka ili do datuma cenzure.

Randomisation was stratified by the presence or absence of cirrhosis and prior treatment experience treatment-naïve versus treatment-experienced.
Randomizacija je bila stratificirana prema prisutnosti ili odsutnosti ciroze i prethodnom liječenju bolesnici koji prethodno nisu liječeni naspram prethodno liječenih bolesnika.

Stratification: Randomisation was stratified by the intended use of ENF in the BR, previous use of darunavir and screening viral load.
Stratifikacija: Randomizacija je bila stratificirana prema namjeri primjene ENF u BR, prethodnoj primjeni darunavira i probiru virusnog opterećenja.

Randomisation was stratified by geographic region, time to progression from the start of first-line therapy(< 6 months versus≥6 months) and disease measurability.
Randomizacija je bila stratificirana prema geografskoj regiji, vremenu od početka prvolinijske terapije do progresije bolesti(< 6 mjeseci naspram ≥ 6 mjeseci) i mjerljivosti bolesti.

Randomisation was stratified by the presence or absence of cirrhosis, HCV genotype(1a versus 1b) and response to prior HCV therapy relapse/breakthrough versus non-response.
Randomizacija je bila stratificirana prema prisutnosti ili odsutnosti ciroze, genotipu HCV-a(1a naspram 1b) i odgovoru na prethodnu terapiju HCV-a relaps/proboj naspram bez odgovora.

Randomisation was stratified by centre, implemented with an independent interactive voice response system, and all study personnel and participants were masked to group assignment.
Randomizacija je stratificirana središtem, provedena s nezavisnim interaktivnim sustavom glasovnog odgovora, a svi kadrovski kadrovi i sudionici bili su maskirani na grupni zadatak.